|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92.32 CHF | +1.97% |
|
+4.94% | +8.78% |
| May. 10 | Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation | MT |
| May. 10 | Novartis Gets FDA Breakthrough Therapy Designation for Scemblix | DJ |
ZURICH (Reuters) - Novartis plans to close a plant in the southern Swiss town of Locarno, the drugmaker said on Wednesday, citing falling demand for testing products.
Around 50 jobs are set to go by shuttering the facility in stages by the end of 2023, it added in a statement.
The Pharmanalytica testing facility in Locarno specialises in performing stability tests and specific release tests for Novartis products.
(Reporting by Michael Shields, editing by Louise Heavens)
| 1st Jan change | Capi. | |
|---|---|---|
| +8.78% | 204B | |
| +30.38% | 695B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 330B | |
| +3.73% | 283B | |
| +16.70% | 239B | |
| -7.93% | 198B | |
| +7.68% | 168B | |
| +5.09% | 125B |
NOVARTIS AG 
